Literature DB >> 31139934

Intra-operative MRI vs endoscopy in achieving gross total resection of pituitary adenomas: a systematic review.

Christian P Soneru1,2, Charles A Riley3, Katherine Hoffman4, Abtin Tabaee3, Theodore H Schwartz5.   

Abstract

BACKGROUND: Intraoperative magnetic resonance imaging (iMRI) is a technology that may improve rates of gross total resection (GTR) for pituitary adenomas. The endoscope is another less expensive technology, which also may maximize resection rates. A direct comparison of these approaches and their additive benefit has never been performed.
METHODS: A systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) standard. PubMed and Embase databases were searched for studies that examined GTR for pituitary adenoma resection with either endoscopic transsphenoidal surgery (eTSS), microscopic transsphenoidal surgery with iMRI (mTSS + iMRI), or endoscopic transsphenoidal surgery with iMRI (eTSS + iMRI).
RESULTS: Eighty-five studies that reported GTR rates in 7124 pituitary adenoma patients were identified. For all pituitary adenomas, eTSS had a pooled proportion of GTR of 68.9% (95% CI 64.7-73.0%) which was similar to that of mTSS + iMRI (GTR 68.3%; 95% CI = 59.4-76.5%) and eTSS + iMRI (GTR 70.7%; 95% CI = 56.9-89.6%). For the subgroup of pituitary macroadenomas, pooled proportions for GTR were similar between eTSS and mTSS + iMRI (eTSS: GTR 59.4%; 95% CI = 49.6-68.7% vs mTSS + iMRI: GTR 68.8%; 95% CI = 57.3-79.3%), and higher for eTSS + iMRI (81.1%; 95% CI = 75.5-86.2%). The post-operative CSF leak proportion for eTSS (4.7%; 95% CI = 3.6-5.9%) was similar to that for eTSS + iMRI (3.7%; 95% CI = 1.6-6.5%) and mTSS + iMRI (4.6%; 95% CI = 2.0-8.3%). No direct statistical comparisons could be performed.
CONCLUSION: Final GTR proportions are similar whether the surgeon uses a microscope supplemented with iMRI or endoscope with or without iMRI. The benefit of the two technologies may be complementary for macroadenomas. These findings are important to consider when comparing the efficacy of different technical strategies in the management of pituitary adenomas.

Entities:  

Keywords:  Endoscopic; Gross total resection; Intra-operative MRI; Pituitary adenoma

Mesh:

Year:  2019        PMID: 31139934     DOI: 10.1007/s00701-019-03955-9

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  5 in total

1.  Estimating Risk of Pituitary Apoplexy after Resection of Giant Pituitary Adenomas.

Authors:  John T Butterfield; Takako Araki; Daniel Guillaume; Ramachandra Tummala; Emiro Caicedo-Granados; Matthew A Tyler; Andrew S Venteicher
Journal:  J Neurol Surg B Skull Base       Date:  2021-02-22

2.  The impact of endoscopic transsphenoidal pituitary adenoma surgery on endocrine function: a single-centre study.

Authors:  Luke Galloway; Mohamed Ali; Andrew Lansdown; Peter Taylor; Aled Rees; John Stephen Davies; Caroline Hayhurst
Journal:  Acta Neurochir (Wien)       Date:  2020-10-21       Impact factor: 2.216

Review 3.  Impact of intraoperative magnetic resonance imaging on gross total resection, extent of resection, and residual tumor volume in pituitary surgery: systematic review and meta-analysis.

Authors:  Victor E Staartjes; Alex Togni-Pogliorini; Vittorio Stumpo; Carlo Serra; Luca Regli
Journal:  Pituitary       Date:  2021-05-04       Impact factor: 4.107

4.  Impact of Intraoperative 3-Tesla MRI on Endonasal Endoscopic Pituitary Adenoma Resection and a Proposed New Scoring System for Predicting the Utility of Intraoperative MRI.

Authors:  Masahiro Tanji; Hiroharu Kataoka; Masahiro Kikuchi; Tatsunori Sakamoto; Fumihiko Kuwata; Mami Matsunaga; Takayuki Nakagawa; Yohei Mineharu; Yoshiki Arakawa; Kazumichi Yoshida; Susumu Miyamoto
Journal:  Neurol Med Chir (Tokyo)       Date:  2020-10-21       Impact factor: 1.742

5.  The Benefit of Intraoperative Magnetic Resonance Imaging in Endoscopic and Microscopic Transsphenoidal Resection of Recurrent Pituitary Adenomas.

Authors:  Andrej Pala; Andreas Knoll; Max Schneider; Gwendolin Etzrodt-Walter; Georg Karpel-Massler; Christian Rainer Wirtz; Michal Hlavac
Journal:  Curr Oncol       Date:  2022-01-17       Impact factor: 3.677

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.